| 2024年年报 | 2023年年报 | |
|---|---|---|
| 营业收入(元) | ||
| CDMO业务(元) | 121,669,600.00 | 63,979,100.00 |
| 授权许可(元) | 66,110,000.00 | 99,286,800.00 |
| 医药制造(元) | 990,903,700.00 | 841,568,100.00 |
| 营业成本(元) | ||
| CDMO业务(元) | 98,903,700.00 | 40,261,600.00 |
| 授权许可(元) | - | - |
| 医药制造(元) | 197,644,000.00 | 180,892,000.00 |
| 毛利(元) | ||
| CDMO业务(元) | 22,765,900.00 | 23,717,500.00 |
| 授权许可(元) | 66,110,000.00 | 99,286,800.00 |
| 医药制造(元) | 793,259,700.00 | 660,676,100.00 |
| 毛利率(%) | ||
| CDMO业务(%) | 18.71 | 37.07 |
| 授权许可(%) | - | - |
| 医药制造(%) | 80.05 | 78.51 |
| 收入构成(%) | ||
| CDMO业务(%) | 10.32 | 6.37 |
| 授权许可(%) | 5.61 | 9.88 |
| 医药制造(%) | 84.07 | 83.75 |
| 毛利构成(%) | ||
| CDMO业务(%) | 2.58 | 3.03 |
| 授权许可(%) | 7.49 | 12.67 |
| 医药制造(%) | 89.92 | 84.30 |